How have ATRA and EQ total returns compared?

Over the past 5 years, ATRA delivered -53.60% and EQ delivered -26.99% annualized total return. Past performance doesn't predict future results.

Atara Biotherapeutics, Inc. (ATRA) vs Equillium, Inc. (EQ)

A side-by-side comparison of Atara Biotherapeutics, Inc. and Equillium, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ATRA

Atara Biotherapeutics, Inc.

$86M

$9.54HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT

Equillium, Inc.

$89M

$1.41HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — ATRA vs EQ

growth of $100 · dividends reinvested · last 8y

ATRA -98.9% (-43.4%/yr)EQ -89.6% (-24.7%/yr)EQ compounded faster over this window

Log scale — wide-divergence pair

ATRA EQ

ATRA vs EQ: by the numbers

•EQ is the larger company ($89M vs $86M market cap).
•Both run net losses; EQ's is the smaller (0.00% vs -269.42% net margin).

Metrics side by side

Valuation

Metric	ATRA	EQ
P/S ratio	13.87	N/A
P/B ratio	N/A	1.59

Profitability

Metric	ATRA	EQ
Gross margin	82.44%	0.00%
Operating margin	29.69%	0.00%
Net margin	-269.42%	0.00%
ROE	N/A	-32.15%
ROIC	-100.35%	-34.10%

Growth (annualized)

Metric	ATRA	EQ
Revenue CAGR (5Y)	56.10%	N/A
Total return CAGR (5Y)	-53.60%	-26.99%

Frequently asked

How have ATRA and EQ total returns compared?: Over the past 5 years, ATRA delivered -53.60% and EQ delivered -26.99% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ATRA analysis Full EQ analysis Interactive comparison tool

Dig into the metrics

Atara Biotherapeutics ROE Equillium ROE Atara Biotherapeutics operating margin Equillium operating margin Atara Biotherapeutics revenue growth Equillium revenue growth Atara Biotherapeutics free cash flow Equillium free cash flow

Atara Biotherapeutics & Equillium appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.